

Are tests of oesophageal (food pipe) function useful and acceptable to patients with eosinophilic oesophagitis?

Submission date 08/09/2022	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 12/09/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 17/01/2025	Condition category Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study aims to improve understanding of the symptoms of eosinophilic oesophagitis (EoE), an inflammatory condition of the oesophagus (food pipe). Tests will be used to see if the oesophagus is working properly and symptoms will be recorded, both before and after a course of treatment. This work will help understand why, despite treatment, a third of patients with EoE continue to have symptoms, making activities such as eating and staying nourished a challenge. EoE affects 10-40 per 100,000 people. This number is increasing, with EoE linked to allergies, triggered by environmental factors or foods. Symptoms include food sticking in the oesophagus. In serious cases, food needs removing during an emergency endoscopy/camera test. EoE is diagnosed if increased eosinophils (cells involved in allergic responses) are found in tissue samples taken during endoscopy. However, treatment currently only addresses whether eosinophils are controlled, not whether the oesophagus works properly.

Who can participate?

Patients aged 18 years or over at participating hospitals with a diagnosis of EoE

What does the study involve?

Two low-risk tests will be used to study the oesophagus in sixty adult patients with EoE. Manometry measures how the muscles in the oesophagus squeeze and clear swallowed material during eating. pH/impedance testing monitors inflammation in the oesophagus. Participants will have each test both before and after receiving treatment. The study will not influence treatment decisions or standard care. Both tests involve passing a thin tube through the nose into the oesophagus. Manometry takes about 20 minutes. pH/impedance testing involves the person going home with the tube (2 mm diameter) in place for 24 hours, with information recorded during quiet periods/sleep. Results will be studied to see how inflammation affects oesophagus muscle function, the passage of food and symptoms. 20 patients will be interviewed to explore how acceptable these tests are in monitoring EoE. This approach will help understand the feasibility of assessing EoE differently in the NHS, making steps towards improving quality of life for those affected.

What are the possible benefits and risks of participating?
Whilst individuals will not directly benefit from participation, major test results will be contextualised and therefore individuals may receive further information about their condition.

Where is the study run from?
Newcastle upon Tyne NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
April 2021 to May 2025

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
Catherine Sykes, c.sykes1@newcastle.ac.uk

Contact information

Type(s)
Scientific

Contact name
Miss Catherine Sykes

ORCID ID
<http://orcid.org/0000-0002-8518-5184>

Contact details
Clinical Measurement Service
Medical Physics Department
Royal Victoria Infirmary
Newcastle upon Tyne
United Kingdom
NE1 4LP
+44 (0)191 282 4493
c.sykes1@newcastle.ac.uk

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
299013

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
IRAS 299013

Study information

Scientific Title

A mixed methods feasibility study into the use of physiological assessment in eosinophilic oesophagitis

Acronym

SWALLeOeW

Study objectives

Observational study to assess the use and acceptability of physiological investigations of oesophageal function in understanding symptoms in eosinophilic oesophagitis (EoE) and to assess the relationship between physiological parameters, symptom profiles and response to treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 19/10/2022, London - Surrey Borders Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, UK; +44 (0)207 104 8104; surreyboundaries.rec@hra.nhs.uk), ref: 22/PR/1086

Study design

Dual-site exploratory mixed-method feasibility study comprising a serial diagnostic study with embedded qualitative design

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Eosinophilic oesophagitis

Interventions

High-resolution manometry (HRM) testing forms the initial part of this serial diagnostic study, assessing oesophageal function during eating in patients with EoE. Comparison will be made to diagnostic gold standards (water swallows) and patient-reported outcome measures (PROMs),

using validated questionnaires for benign oesophageal motility disorders. HRM will be repeated following a treatment episode to assess for motility changes following treatment administered as part of standard care.

pH/impedance monitoring forms the second part of the study, evaluating the use of mucosal impedance measurements in monitoring EoE status before and after standard therapy, with patients undergoing tests directly following HRM. Mucosal impedance will be measured to assess its practicability as a marker of mucosal integrity during quiescent nocturnal periods.

Finally, a qualitative approach, using semi-structured interviews, will be used to explore themes surrounding the acceptability of tests to monitor disease status in individuals with EoE.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

-

Primary outcome measure

1. Recruitment rate, recorded as the number of eligible participants who consent to participate in the study during the 21-month recruitment period
2. Attrition rate, assessed using the number of consented participants who do not remain in the study until the end of follow-up, defined as completing physiological assessments on visit 1 (single day) and where new medication is initiated, repeat investigations 2-4 months following this

Secondary outcome measures

1. Swallowing parameters measured whilst participants eat a solid test meal using high-resolution manometry at visit 1/baseline (before any new treatment is instigated as part of routine clinical care) and at 2-4 months after a new treatment is instigated as part of routine clinical care where applicable
2. Temporal relationship between symptoms and swallowing parameters measured using high-resolution manometry during the solid test meal consumption both at visit 1/baseline and 2-4 months after a new treatment is instigated as part of routine clinical care where applicable
3. Mean nocturnal baseline impedance of the oesophageal mucosa measured using 24-hour ambulatory pH/impedance testing at visit 1/baseline (before a new treatment is instigated as part of routine clinical care) and at 2-4 months after a new treatment is instigated as part of routine clinical care where applicable
4. Gastro-oesophageal reflux exposure measured using 24-hour ambulatory pH/impedance testing at visit 1/baseline (before a new treatment is instigated as part of routine clinical care) and 2-4 months after a new treatment is instigated as part of routine clinical care where applicable
5. Dysphagia, reflux symptoms and oesophageal hypervigilance and anxiety measured using the Brief Esophageal Dysphagia Questionnaire, Reflux Disease Questionnaire and the Esophageal Hypervigilance and Anxiety Scale respectively, at visit 1 and 2-4 months after a new treatment is initiated (where applicable)
6. Routine markers of eosinophilic oesophagitis (e.g. histology, endoscopic appearances) measured as part of routine care will be compared to study findings from closest visits, e.g.

baseline endoscopy compared to baseline tests and follow-up endoscopy 2-4 months after treatment initiation compared to follow-up tests

Overall study start date

01/04/2021

Completion date

28/02/2026

Eligibility

Key inclusion criteria

1. Patients from County Durham and Darlington NHS Foundation Trust (CDDFT) or University College London Hospitals (UCLH)
2. Aged 18 years or over
3. New diagnosis of eosinophilic oesophagitis (>15/high-powered field (hpf) or 0.3 mm² on oesophageal biopsy and index oesophageal symptoms
4. Known diagnosis of eosinophilic oesophagitis (current histological and symptom status documented but does not impact inclusion)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

60

Key exclusion criteria

1. <18 years old
2. Current involvement in a Clinical Trial of an Investigational Medicinal Product (CTIMP) for eosinophilic oesophagitis (EoE)
3. Eosinophilia as a result of other known causes (local or systemic)
4. Oesophageal stricture on oesophagogastric duodenoscopy
5. Previous upper GI surgery
6. Active oesophageal comorbidity including Barrett's oesophagus, oesophageal varices, coagulation disorders
7. Significant nasopharyngeal pathology, preventing nasogastric intubation
8. Opiate use
9. Unable to provide informed consent
10. Limited verbal communication
11. Non English speaker

Date of first enrolment

07/10/2022

Date of final enrolment

31/08/2025

Locations

Countries of recruitment

England

United Kingdom

Study participating centre**University Hospital of North Durham**

University Hospital of Durham

Dryburn Hospital

North Road

Durham

United Kingdom

DH1 5TW

Study participating centre**University College London Hospital**

235 Euston Road

London

United Kingdom

NW1 2BU

Study participating centre**Darlington Memorial Hospital**

Hollyhurst Road

Darlington

United Kingdom

DL3 6HX

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust

Sponsor details

Newcastle Joint Research Office
Level 1, Regent Point
Regent Farm Road
Gosforth
Newcastle upon Tyne
England
United Kingdom
NE3 3HD
+44 (0)191 282 5789
aaron.jackson@nhs.net

Sponsor type

Hospital/treatment centre

Website

<http://www.newcastle-hospitals.org.uk/>

ROR

<https://ror.org/05p40t847>

Funder(s)**Funder type**

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Three publications planned in high-impact peer-reviewed journals.

Intention to publish date

01/12/2026

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon appropriate request at the end of the study period from Catherine Sykes (c.sykes1@newcastle.ac.uk). Written informed consent will be obtained for every participant regarding data use of this nature and any data shared would be anonymised prior to sharing. Data will be available for a minimum of 5 years.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 1.1	05/10/2022	24/11/2022	No	No
HRA research summary			28/06/2023	No	No
Protocol file	version 1.2	31/01/2024	01/03/2024	No	No
Protocol file	version 1.3		30/05/2024	No	No